# DESCRIPTION

## FIELD OF THE INVENTION

- relate to breast cancer classification

## BACKGROUND OF THE INVENTION

- introduce breast cancer statistics
- summarize current prognosis methods

## SUMMARY OF THE INVENTION

- introduce PAM50 classification model

## DETAILED DESCRIPTION OF THE INVENTION

### Overview

- introduce breast cancer treatment challenges
- define breast cancer
- describe breast cancer heterogeneity
- motivate gene expression profiling
- summarize intrinsic subtypes
- describe limitations of unsupervised clustering
- introduce PAM50 classification model

### Clinical Variables

- describe clinical variables for breast cancer prognosis
- introduce risk of relapse (ROR) score

### Sample Source

- define subject and subject sample
- describe biological sample sources
- specify sample collection methods

### Expression Profiling

- introduce pattern recognition algorithms
- describe multivariate statistical analysis modeling
- contrast unsupervised and supervised approaches
- detail supervised method for PAM50 classification model
- describe nearest centroid methodology

### Detection of Intrinsic Gene Expression

- define detecting expression of intrinsic genes
- list methods for detecting expression
- describe PCR-based methods
- describe array-based methods
- explain microarray technology
- describe RNA extraction methods
- describe quantitative RT-PCR
- describe microarray analysis
- explain use of QPCR for gene measurement
- describe microarray data analysis
- explain use of dual color fluorescence
- describe development of microarray methods

### Data Processing

- describe pre-processing gene expression data
- explain scaling and weighting methods
- describe translation of descriptor coordinate axes
- explain normalization methods
- describe mean centering and unit variance scaling
- explain logarithmic scaling and equal range scaling

### Calculation of Risk of Relapse

- describe predicting breast cancer outcome
- explain classification of subjects according to subtype
- describe calculation of Risk Of Relapse (ROR) score
- explain use of Cox Proportional Hazards Model Analysis
- describe calculation of ROR using subtype distances and clinical variables

### Prediction of Response to Therapy

- introduce breast cancer treatment strategies
- motivate PAM50 model for risk stratification
- describe application of PAM50 model in treatment decisions
- discuss limitations of conventional clinical assays
- define predicting response to therapy
- describe calculation of proliferation-weighted PAM50 risk score

### Kits

- introduce kits for breast cancer intrinsic subtypes and prognosis
- describe array-based kits with capture probes
- describe primer-based kits for gene expression detection
- discuss database storage of molecular signatures

## EXPERIMENTAL

### Example 1

- describe patient cohorts
- detail sample collection and processing
- outline nucleic acid extraction methods
- describe reverse transcription and real-time quantitative PCR
- detail microarray data processing
- describe pre-processing of microarray data
- identify prototypical intrinsic subtype samples and genes
- reduce gene set using prototype samples and qRT-PCR
- predict sample subtypes
- compare reproducibility of classification methods
- construct centroids for classification
- assess prognostic significance of intrinsic subtype classification
- develop risk models with clinical and molecular data
- train risk of relapse models
- assign risk scores to test cases
- compare risk models
- analyze relationship between ROR score and relapse-free survival
- create new subtype model based on prototypical samples and genes
- distribute biological subtypes across ER positive and ER-negative tumors
- analyze subtypes and response to neoadjuvant T/FAC treatment
- predict risk of relapse based on biological subtype

## Example 2

### Introduction and Background Data

- introduce neoadjuvant endocrine therapy for breast cancer

### Summary

- summarize PAM50-based intrinsic subtype classifier
- summarize predictive and prognostic properties of PAM50 model

### Methodology:

- describe National Cancer Institute sponsored Phase 2 trial

### Results:

- describe changes in PAM50 intrinsic subtype and proliferation weighted risk score
- describe correlation with Ki67 immunohistochemistry
- describe clinical correlations with PAM50 intrinsic subtype and risk score

## Example 3

- describe risk of relapse analysis using clinical and molecular subtype data

### Prognostic and Predictive Models Using Clinical and Molecular Subtype Data:

- describe development of risk models with clinical and molecular data

### Comparison of Relapse Prediction Models

- compare relapse prediction models using C-index

### Risk of Relapse Models for Prognosis in Node-Negative Breast Cancer

- describe Cox models for prognosis in node-negative breast cancer

### Subtypes and Prediction of Response to Neoadjuvant T/FAC Treatment

- describe relationship between subtypes and clinical markers in predicting response to neoadjuvant T/FAC treatment

## Example 4

- introduce study on PAM50 classifier in estrogen receptor positive breast cancer patients

### Patients:

- describe patient cohort and selection criteria

### RNA Preparation:

- outline RNA extraction and quality control process

### Assignment of Biological Subtype to Clinical Samples:

- describe construction of gene expression centroids and assignment of intrinsic subtypes

### Relation of PAM50 Subtype to Clinical Outcome:

- perform Kaplan-Meier and Cox regression analyses to assess prognostic significance of PAM50 subtype

### Relation of Risk-Of-Relapse (ROR) Score to Clinical Outcome:

- describe calculation and validation of ROR score and its prognostic significance

### Results

- summarize patient characteristics and PAM50 subtype assignments
- present Kaplan-Meier analysis of PAM50 subtype and clinical outcome
- describe multivariate Cox regression analysis of PAM50 subtype and clinical outcome
- present ROR score and its prognostic significance
- describe interaction between ROR score and nodal status
- present comparison of PAM50 and immunohistochemical subtyping
- describe concordance between PAM50 and immunohistochemical subtyping
- present multivariate Cox regression analysis of PAM50 and immunohistochemical subtyping
- describe comparison of Adjuvant! and ROR models
- present Kaplan-Meier analysis of ROR score and clinical outcome in Adjuvant! risk groups

### Discussion

- summarize findings on PAM50 subtype and clinical outcome
- discuss implications for treatment of breast cancer patients
- describe advantages of PAM50 qPCR assay over other prognostic tools
- discuss limitations of clinical measurements of ER and HER2 status
- describe potential of PAM50 assay to identify hormone-independent tumors
- discuss comparison of PAM50 and immunohistochemical subtyping
- summarize conclusions on PAM50 assay and its clinical utility

